To study baseline serum testosterone’s prognostic value in hormone naïve advanced prostate cancer patients receiving continuous androgen deprivation therapy.
The study population undergoing continuous androgen deprivation therapy (agonist or antagonist) with 1-year follow-up was pooled for post-hoc analysis from two large prospective, randomized, parallel-arm phase 3b trials (NCT00295750-Global; NCT00928434-USA).